Drug Profile
IPR 2000
Latest Information Update: 31 Jan 2001
Price :
$50
*
At a glance
- Originator Institute for Pharmaceutical Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 31 Jan 2001 No-Development-Reported for Obesity in Switzerland (Unknown route)
- 25 May 1998 Phase-II clinical trials for Obesity in Switzerland (Unknown route)